These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802 [TBL] [Abstract][Full Text] [Related]
4. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
5. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation. Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385 [TBL] [Abstract][Full Text] [Related]
6. Neoral use in the cardiac transplant recipient. Valantine H Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748 [TBL] [Abstract][Full Text] [Related]
7. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050 [TBL] [Abstract][Full Text] [Related]
8. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group. Brennan DC; Barbeito R; Burke J; Brayman K; Greenstein S; Chang T Kidney Int; 1999 Aug; 56(2):685-91. PubMed ID: 10432409 [TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. van Mourik ID; Thomson M; Kelly DA Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group. Pollak R; Wong RL; Chang CT Ther Drug Monit; 1999 Dec; 21(6):661-3. PubMed ID: 10604829 [TBL] [Abstract][Full Text] [Related]
11. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. White M; Pelletier GB; Tan A; Jesina C; Carrier M J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770 [TBL] [Abstract][Full Text] [Related]
13. Safe conversion to cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients. Kahn D; Muller E; Pascoe M Saudi J Kidney Dis Transpl; 2010 May; 21(3):426-32. PubMed ID: 20427863 [TBL] [Abstract][Full Text] [Related]
14. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P; Niese D Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620 [TBL] [Abstract][Full Text] [Related]
16. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Grant D; Kneteman N; Tchervenkov J; Roy A; Murphy G; Tan A; Hendricks L; Guilbault N; Levy G Transplantation; 1999 Apr; 67(8):1133-7. PubMed ID: 10232563 [TBL] [Abstract][Full Text] [Related]
17. Neoral conversion from Sandimmune in maintenance renal transplant patients: an individualized approach. Curtis JJ; Lynn M; Jones PA J Am Soc Nephrol; 1998 Jul; 9(7):1293-300. PubMed ID: 9644641 [TBL] [Abstract][Full Text] [Related]
19. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation. Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710 [TBL] [Abstract][Full Text] [Related]
20. Kaposi's sarcoma in renal-transplant recipients: experience at the Catholic University in Rome, 1988-1996. Lesnoni La Parola I; Masini C; Nanni G; Diociaiuti A; Panocchia N; Cerimele D Dermatology; 1997; 194(3):229-33. PubMed ID: 9187838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]